BC
CLDI icon

Barrett & Company’s Calidi Biotherapeutics CLDI Stock Holding History

Barrett & Company’s Portfolio CLDI Stock Details CLDI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-292
Closed -$342 – 656
2025
Q4 		$342 Hold
292
– – ﹤0.01% 648
2025
Q3 		$444 Hold
292
– – ﹤0.01% 625
2025
Q2 		$805 Hold
292
– – ﹤0.01% 611
2025
Q1 		$1.98K Hold
292
– – ﹤0.01% 553
2024
Q4 		$4.03K Buy
+292
New +$5.48K ﹤0.01% 516

Other funds holding CLDI

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
WAM
Warberg Asset Management Winnetka, Illinois $600M AUM 23.37% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RCI
RS Crum Inc Newport Beach, California $517M AUM 16.68% 1-Year Est. Return
AAP
Arax Advisory Partners Denver, Colorado $3.54B AUM 19.14% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Barrett & Company's CLDI Position: Q1 2026 in Review

Barrett & Company sold out of Calidi Biotherapeutics (CLDI) in Q1 2026, closing a stake of 292 shares — an estimated $342 sold.

Barrett & Company first reported a position in CLDI in Q4 2024 and held it in 5 quarters. The position peaked at $4.03K in Q4 2024. 28 funds tracked by Wall St. Rank hold CLDI as of Q1 2026.

  • Barrett & Company reported no remaining Calidi Biotherapeutics position as of Q1 2026 after selling out during the quarter.
  • Barrett & Company sold 292 Calidi Biotherapeutics shares in Q1 2026, an estimated $342.
  • Barrett & Company first reported a position in Calidi Biotherapeutics in Q4 2024 and held it in 5 quarters.
  • Barrett & Company's Calidi Biotherapeutics position peaked at $4.03K in Q4 2024.
  • 28 funds tracked by Wall St. Rank held Calidi Biotherapeutics as of Q1 2026.

Based on Barrett & Company's 13F filing for Q1 2026, filed 4 May 2026.